osteoclasts,3 the cells that are responsible for bone resorption.
Because of this unique and selective cellular distribution, it is
believed that cathepsin K plays a key role in the osteoclast-
mediated degradation of bone matrix. It has also been reported
that cathepsin K can attack the collagen of adult human bone,
which constitutes 90% of the organic matrix in bone.4 It is
postulated that molecules capable of selectively inhibiting
cathepsin K may serve as useful therapeutic agents against
diseases such as osteoporosis and other bone disorders involving
excessive bone loss.
As part of an ongoing drug discovery program at our
laboratories, compound 15 was identified as a highly potent and
selective inhibitor of cathepsin K. To enable further study of
the pharmacological properties of 1, we sought a scaleable
chromatography-free synthesis suitable for the preparation of
this compound in multigram quantities. A notable feature of 1
is the chiral, nonbasic R-trifluoromethylbenzylamine moiety
(pKa ∼ 1.5). Stereoselective methods for the synthesis of
perfluoroalkylamines have been the subject of recent reviews,6
and several approaches were envisioned to achieve the synthesis
of 1. However, we were particularly interested in exploring
synthetic routes from (S)-leucine derivatives given their com-
mercial availability and the possibility of using the stereocenter
to install the R-trifluoromethylamine center of 1 in a diaste-
reoselective manner.
Diastereoselective Arylithium Addition to an
r-Trifluoromethyl Imine. Practical Synthesis of a
Potent Cathepsin K Inhibitor
Ame´lie Roy,†,* Francis Gosselin,† Paul D. O’Shea,† and
Cheng-y. Chen‡
Department of Process Research, Merck Frosst Centre for
Therapeutic Research, 16711 Trans Canada Highway,
Kirkland, Que´bec H9H 3L1, Canada, and Department of
Process Research, Merck Research Laboratories,
Post Office Box 2000, Rahway, New Jersey 07065
ReceiVed NoVember 24, 2005
Our retrosynthetic analysis of 1 is illustrated in Scheme 1.
We envisioned that the key (S)-R-trifluoromethylamine stereo-
center could be set via diastereoselective addition of 4-bro-
mophenyllithium to imine 4. Subsequent Suzuki cross-coupling
followed by sulfur and carbon oxidations would afford biaryl
acid 8. Amide coupling with commercially available aminoac-
etonitrile hydrochloride would complete the synthesis of 1.
The condensation of (S)-leucinol 2 with trifluoroacetaldehyde
methyl hemiacetal 3 in toluene in the presence of a catalytic
amount of pyridinium p-toluenesulfonate (PPTS) with the
azeotropic removal of water/MeOH did not yield the desired
imine 4. Instead oxazolidine 5 was obtained as an ∼2:1 mixture
A practical, chromatography-free synthesis of potent cathe-
psin K inhibitor 1 is described. The addition of 4-bromophe-
nyllithium to an R-trifluoromethylimine derived from com-
mercially available (S)-leucinol was accomplished in a highly
diastereoselective manner (97.6% de, 91% yield). Subsequent
Suzuki cross-coupling afforded biaryl 7. Oxidation of the
alcohol and sulfide functionalities led to the formation of
carboxylic acid 8. Crystallization of 7 and acid 8 as its
dicyclohexylamine salt gave excellent impurity rejection. The
final amide coupling with commercially available aminoac-
etonitrile hydrochloride afforded 1 in excellent purity
(99.6A% by HPLC, 100% de, <3 ppm Pd, W, Cr).
(3) (a) Bromme, D.; Okamoto, K.; Wang, B. B.; Biroc, S. J. Biol. Chem.
1996, 271, 2126. (b) Bossard, M. J.; Tomaszek, T. A.; Thompson, S. K.;
Amegadzie, B. Y.; Hanning, C. R.; Jones, C.; Kurdyla, J. T.; McNulty, D.
E.; Drake, F. H.; Gowen, M.; Levy, M. A. J. Biol. Chem. 1996, 271, 12517.
(c) Tezuka, K.; Tezuka, Y.; Maejima, A.; Sato, T.; Nemoto, K.; Kamioka,
H.; Hakeda, Y.; Kumegawa, M. J. Biol. Chem. 1994, 269, 1106.
(4) Garnero, P.; Borel, O.; Byrjalsen, I.; Ferras, M.; Drake, F. H.;
McQueney, M. S.; Fogged, N. T. Delmas, P. D.; Delaisse, J. M. J. Biol.
Chem. 1998, 273, 32347.
(5) Li, C. S.; Descheˆnes, D.; Desmarais, S.; Falgueyret, J.-P.; Gauthier,
J. Y.; Kimmel, D. B.; Le´ger, S.; Masse´, F.; McKay, D. J.; Percival, M. D.;
Riendeau, D.; Rodan, S. B.; Somoza, J. R.; The´rien, M.; Truong, V.-L.;
Wesolowski, G.; Zamboni, R.; Black, W. C. Bioorg. Med. Chem. Lett. 2006,
16, 1985.
(6) (a) Enantiocontrolled Synthesis of Fluoro-Organic Compounds;
Soloshonok, V. A., Ed.; Wiley: Chichester, 1999. (b) Asymmetric Fluo-
roorganic Chemistry: Synthesis, Applications and Future Directions;
Ramachandran, P. V., Ed.; American Chemical Society; Washington, DC,
1999. (c) Pirkle, W. H.; Hauske, J. R. J. Org. Chem. 1977, 42, 2436. (d)
Wang, Y.; Mosher, H. S. Tetrahedron Lett. 1991, 32, 987. (e) Abe, H.;
Amii, H.; Uneyama, K. Org. Lett. 2001, 3, 313. (f) Sakai, T.; Yan, F.;
Kashino, S.; Uneyama, K. Tetrahedron 1996, 52, 233. (g) Enders, D.;
Funabiki, K. Org. Lett. 2001, 3, 1575. (h) Soloshonok, V. A.; Avilov, D.
V.; Kukhar, V. P.; Van Meervelt, L.; Mischenki, N. Tetrahedron Lett. 1997,
38, 4671. (h) Prakash, G. K. S.; Mandal, M.; Olah, G. A. Org. Lett. 2001,
3, 2847. (i) Prakash, G. K. S.; Mandal, M.; Olah, G. A. Angew. Chem., Int.
Ed. 2001, 40, 589.
Osteoporosis is a disease characterized by low bone mass,
resulting in skeletal fragility and a greater risk of fracture. It is
known as the “silent disease”, as bone loss often progresses
over a number of years without showing any symptoms. In the
United States alone, 10 million individuals are reported to
already have osteoporosis and another 34 million are estimated
to have low bone mass, placing them at an increased risk for
osteoporosis. Each year, this disease is also responsible for more
than 1.5 million fractures.1 Cathepsin K, a member of the papain
superfamily of cysteine proteases and one of a growing number
of cysteinyl cathepsins (B, H, L, S, C, K, O, F, V, X, and W),2
has been shown to be abundantly and selectively expressed in
† Merck Frosst Centre for Therapeutic Research.
‡ Merck Research Laboratories.
(1) About Osteoporosis, Fast Facts Sheet; National Osteoporosis Founda-
tion: Washington, DC, October, 2004 (www.nof.org.).
(2) Drake, F. H.; Dodds, R. A.; James, I. E.; Connor, J. R.; Debouck,
C.; Richardson, S.; Lee-Rykaczewski, E.; Coleman, L.; Rieman, D.;
Barthlow, R.; Hastings, G.; Gowen, M. J. Biol. Chem. 1996, 271, 12511.
10.1021/jo052430j CCC: $33.50 © 2006 American Chemical Society
Published on Web 05/03/2006
4320
J. Org. Chem. 2006, 71, 4320-4323